Eastwood Bio-Medical Canada Inc (TSE:EBM)

:EBM

EBM

Eastwood Bio-Medical Canada

RESEARCH TOOLSreports

Want to see TSE:EBM full AI Analyst Report?

Eastwood Bio-Medical Canada (EBM) Price & Analysis

5 Followers

EBM Stock Chart & Stats

C$0.80

>-C$0.01(-1.00%)

At close: Jan 08 4:00 PM EST

C$0.80

>-C$0.01(-1.00%)

Day’s Range― - ―

52-Week RangeC$0.30 - C$1.10

Previous CloseN/A

Volume2.20K

Average Volume (3M)3.49K

Market Cap

C$48.22M

Enterprise ValueC$66.06M

Total Cash (Recent Filing)C$13.46K

Total Debt (Recent Filing)C$74.67K

Price to Earnings (P/E)―

Beta-0.06

Next Earnings

Jun 25, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding68,885,970

10 Day Avg. Volume3,055

30 Day Avg. Volume3,488

Financial Highlights & Ratios

PEG Ratio5.31

Price to Book (P/B)-29.59

Price to Sales (P/S)61.66

P/FCF Ratio2.50K

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross Margin (~63%)A ~63% gross margin indicates durable product-level economics and pricing power for core supplements. Sustained gross margin provides room to invest in R&D, marketing and distribution to scale revenue and supports longer-term path to operating leverage if SG&A growth is controlled.

Recent Positive Operating And Free Cash FlowThe shift to positive operating and free cash flow, albeit small, shows improving cash conversion from operations. This structural move reduces immediate funding pressure, supports working-capital needs and demonstrates early operational improvements that can compound if revenue stabilizes.

Research-backed Products & Multi-channel DistributionA research-backed flagship product plus online, retail and direct channels creates a resilient go-to-market mix. Diversified distribution reduces single-channel risk, and scientific positioning supports premium pricing and differentiation, helping sustain demand over multiple market cycles.

Bears Say

Deep And Persistent LossesPersistent large net losses and negative operating margins erode retained capital and limit the firm's ability to self-fund growth. Over time this constrains reinvestment in product development and distribution expansion and raises the need for external funding or structural cost reductions.

Negative Shareholders' Equity (~-$1.65M)Negative equity is a structural balance-sheet weakness that reduces financial flexibility, complicates access to capital markets and increases solvency risk. It limits capacity to absorb shocks, constrains borrowing options, and can force dilutive financing or asset sales to restore equity.

TTM Revenue Declined (-8.0%)Declining trailing revenues undermine scale economics and make margin recovery harder despite strong gross margins. A downward revenue trend can signal weakening market adoption or distribution execution, reducing the likelihood that fixed costs will be absorbed and profitability restored.

EBM FAQ

What was Eastwood Bio-Medical Canada Inc’s price range in the past 12 months?

Eastwood Bio-Medical Canada Inc lowest stock price was C$0.29 and its highest was C$1.10 in the past 12 months.

What is Eastwood Bio-Medical Canada Inc’s market cap?

Eastwood Bio-Medical Canada Inc’s market cap is C$48.22M.

When is Eastwood Bio-Medical Canada Inc’s upcoming earnings report date?

Eastwood Bio-Medical Canada Inc’s upcoming earnings report date is Jun 25, 2026 which is in 33 days.

How were Eastwood Bio-Medical Canada Inc’s earnings last quarter?

Currently, no data Available

Is Eastwood Bio-Medical Canada Inc overvalued?

According to Wall Street analysts Eastwood Bio-Medical Canada Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Eastwood Bio-Medical Canada Inc pay dividends?

Eastwood Bio-Medical Canada Inc does not currently pay dividends.

What is Eastwood Bio-Medical Canada Inc’s EPS estimate?

Eastwood Bio-Medical Canada Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Eastwood Bio-Medical Canada Inc have?

Eastwood Bio-Medical Canada Inc has 68,885,970 shares outstanding.

What happened to Eastwood Bio-Medical Canada Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Eastwood Bio-Medical Canada Inc?

Currently, no hedge funds are holding shares in TSE:EBM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Eastwood Bio-Medical Canada Inc

Eastwood Bio-Medical Canada Inc. markets and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. It distributes Eleotin that provide natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. The company's licensed products include Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 for laxative; Eleotin Cal20 for bone and teeth maintenance; Eleotin V3D for development and maintenance of bones, teeth, and good health; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; and Eleotin Zn330 for tissue formation and metabolism. Its products also include Eleotin Bentley to promote healthy glucose levels; and Eleotin LBM for hypertension relief. The company was incorporated in 2010 and is based in Richmond, Canada.